236 related articles for article (PubMed ID: 35557575)
21. Transarterial chemoembolization plus immune checkpoint inhibitor as postoperative adjuvant therapy for hepatocellular carcinoma with portal vein tumor thrombus: A multicenter cohort study.
Yuan L; Feng J; Zhang Y; Lu C; Xu L; Liang C; Liu Z; Mao F; Xiang Y; Wang W; Wang K; Cheng S
Eur J Surg Oncol; 2023 Jul; 49(7):1226-1233. PubMed ID: 36739252
[TBL] [Abstract][Full Text] [Related]
22. DEM-TACE as the initial treatment could improve the clinical efficacy of the hepatocellular carcinoma with portal vein tumor thrombus: a retrospective controlled study.
Chen J; Lai L; Luo J; Wang H; Li M; Huang M
BMC Cancer; 2022 Nov; 22(1):1242. PubMed ID: 36451104
[TBL] [Abstract][Full Text] [Related]
23. Transarterial Chemoembolization Combined With Apatinib Plus PD-1 Inhibitors for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Multicenter Retrospective Study.
Xia WL; Zhao XH; Guo Y; Hu HT; Cao GS; Li Z; Fan WJ; Xu SJ; Li HL
Clin Transl Gastroenterol; 2023 May; 14(5):e00581. PubMed ID: 36920551
[TBL] [Abstract][Full Text] [Related]
24. Treatment response, survival and safety profile of transarterial chemoembolization using different sizes of drug-eluting beads in hepatocellular carcinoma patients with portal vein tumor thrombus.
Lyu T; Yao H; Wang J; Song L; Tong X; Zou Y
Clin Res Hepatol Gastroenterol; 2022 Apr; 46(4):101819. PubMed ID: 34619365
[TBL] [Abstract][Full Text] [Related]
25. Radiotherapy prior to or after transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with portal vein tumor thrombus: a randomized controlled trial.
Guo L; Wei X; Feng S; Zhai J; Guo W; Shi J; Lau WY; Meng Y; Cheng S
Hepatol Int; 2022 Dec; 16(6):1368-1378. PubMed ID: 36271176
[TBL] [Abstract][Full Text] [Related]
26. Comparative efficacy and safety of multimodality treatment for advanced hepatocellular carcinoma with portal vein tumor thrombus: patient-level network meta-analysis.
Leung JH; Wang SY; Leung HWC; Chan ALF
Front Oncol; 2024; 14():1344798. PubMed ID: 38434681
[TBL] [Abstract][Full Text] [Related]
27. Anlotinib followed by transarterial chemoembolization and radiofrequency ablation is a safe and effective initial treatment for hepatocellular carcinoma patients with portal vein tumor thrombus: A retrospective case series study.
Wang J; Li X; Wang F; Shi D; Zhang J
J Cancer Res Ther; 2021 Jul; 17(3):619-624. PubMed ID: 34269290
[TBL] [Abstract][Full Text] [Related]
28. Combination Therapy of Chemoembolization and Hepatic Arterial Infusion Chemotherapy in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis Compared with Chemoembolization Alone: A Propensity Score-Matched Analysis.
Liu BJ; Gao S; Zhu X; Guo JH; Kou FX; Liu SX; Zhang X; Wang XD; Cao G; Chen H; Liu P; Zhu LZ; Xu HF; Yang RJ
Biomed Res Int; 2021; 2021():6670367. PubMed ID: 34337041
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombus: A Systematic Review and Meta-Analysis.
Deng J; Liao Z; Gao J
Curr Oncol; 2023 Jan; 30(1):1243-1254. PubMed ID: 36661745
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of transarterial chemoembolization combined with lenvatinib and PD-1 inhibitor in the treatment of advanced hepatocellular carcinoma: A meta-analysis.
Wang L; Lin L; Zhou W
Pharmacol Ther; 2024 May; 257():108634. PubMed ID: 38499069
[TBL] [Abstract][Full Text] [Related]
31. Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: A comparative retrospective study.
Zhang JX; Chen YX; Zhou CG; Liu J; Liu S; Shi HB; Zu QQ
Hepatol Res; 2022 Sep; 52(9):794-803. PubMed ID: 35698267
[TBL] [Abstract][Full Text] [Related]
32. Advanced hepatocellular carcinoma treated by transcatheter arterial chemoembolization with drug-eluting beads plus lenvatinib versus sorafenib, a propensity score matching retrospective study.
Xue M; Wu Y; Zhu B; Zou X; Fan W; Li J
Am J Cancer Res; 2021; 11(12):6107-6118. PubMed ID: 35018245
[TBL] [Abstract][Full Text] [Related]
33. Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors Versus Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma with First- or Lower-Order Portal Vein Tumor Thrombosis.
Zhang JX; Cheng Y; Wei J; Fan WL; Liu J; Zhou CG; Liu S; Shi HB; Chu XY; Zheng WL; Zu QQ
Cardiovasc Intervent Radiol; 2024 Apr; ():. PubMed ID: 38671322
[TBL] [Abstract][Full Text] [Related]
34. Comparison of drug-eluting bead with conventional transcatheter arterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: A randomized clinical trial.
Zhou TY; Tao GF; Zhou GH; Zhang YL; Zhu TY; Chen SQ; Wang HL; Wang BQ; Jing L; Chen F
Int J Surg; 2024 May; ():. PubMed ID: 38775550
[TBL] [Abstract][Full Text] [Related]
35. The treatment of transarterial chemoembolization/hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitor is effective against hepatocellular carcinoma with portal vein tumor thrombus: A systematic review.
Yuanren G; Yin L; Liu R; Cui Y
Front Oncol; 2023; 13():1054072. PubMed ID: 36969065
[TBL] [Abstract][Full Text] [Related]
36. Transarterial Chemoembolization Combined With Lenvatinib Plus PD-1 Inhibitor for Advanced Hepatocellular Carcinoma: A Retrospective Cohort Study.
Cai M; Huang W; Huang J; Shi W; Guo Y; Liang L; Zhou J; Lin L; Cao B; Chen Y; Zhou J; Zhu K
Front Immunol; 2022; 13():848387. PubMed ID: 35300325
[TBL] [Abstract][Full Text] [Related]
37. Hepatocellular Carcinoma With Portal Vein Tumor Thrombus Treated With Transarterial Chemoembolization and Sorafenib
Hu HT; Luo JP; Cao GS; Li Z; Jiang M; Guo CY; Yuan H; Yao QJ; Geng X; Park JH; Cheng HT; Jiang L; Ma JL; Zhao Y; Li HL
Front Oncol; 2021; 11():806907. PubMed ID: 35004330
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of transcatheter arterial chemoembolization combined with either
Li Y; Li H; Hu H; Yuan H; Zhao Y
J Cancer Res Ther; 2020; 16(7):1691-1697. PubMed ID: 33565518
[TBL] [Abstract][Full Text] [Related]
39. Lenvatinib with or without Concurrent Drug-Eluting Beads Transarterial Chemoembolization in Patients with Unresectable, Advanced Hepatocellular Carcinoma: A Real-World, Multicenter, Retrospective Study.
Xia D; Bai W; Wang E; Li J; Chen X; Wang Z; Huang M; Huang M; Sun J; Yang W; Lin Z; Wu J; Li Z; Yang S; Zhu X; Chen Z; Zhang Y; Fan W; Mai Q; Ding R; Nie C; Feng L; Li X; Huang W; Sun J; Wang Q; Lv Y; Li X; Luo B; Wang Z; Yuan J; Guo W; Li K; Li B; Li R; Yin Z; Xia J; Han G
Liver Cancer; 2022 Jul; 11(4):368-382. PubMed ID: 35978600
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of endovascular brachytherapy combined with transarterial chemoembolization for the treatment of hepatocellular carcinoma patients with type III or IV portal vein tumor thrombosis.
Li L; Cheng N; Huang X; Weng X; Jiao Y; Liu J; Guo W
World J Surg Oncol; 2022 Feb; 20(1):30. PubMed ID: 35109883
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
